Types of Peptides
Complete Classification Guide for Function, Delivery & Legal Status 2026
Therapeutic peptides are short amino acid chains that act as biological signals — telling cells to release hormones, repair tissue, regulate appetite, or modulate immune response. Most require injection, most require a physician prescription, and the gap between vendor claims and published clinical evidence is real. This guide maps the full classification framework so you can evaluate any peptide across three axes: what it does, how you take it, and whether you can legally access it.
Key takeaways
- Every therapeutic peptide can be classified three ways at once: function (what it does), route (how you take it), and regulatory status (whether you can legally access it in the US).
- Seven functional categories cover the full therapeutic range: growth hormone, weight loss, healing, anti-aging, cognitive, immune/metabolic, and sexual health.
- SubQ injection delivers 90–100% bioavailability. Oral semaglutide (Rybelsus) — the most engineered oral peptide available — achieves only 0.4–1% bioavailability even with SNAC absorption technology (FDA prescribing information, 2024).
- As of 2026, fewer than 10 peptides hold FDA approval for specific indications. Most therapeutic peptides require a physician prescription and are filled at licensed compounding pharmacies.
- The 2026 WADA Prohibited List (in force January 1, 2026) bans all GH-releasing factors and secretagogues under Section S2.2.4, including CJC-1295, sermorelin, ipamorelin, GHRP-2, and MK-677.
Before you start All therapeutic peptides for human use — including compounded peptides available through 503A and 503B pharmacies — require a valid prescription from a licensed physician. No classification framework replaces an individual physician evaluation.
The three-axis classification framework
Therapeutic peptides contain 2 to 50 amino acids and act as biological signaling molecules. Unlike most synthetic drugs, they work within the body’s existing feedback systems rather than bypassing them — a key reason for their generally favorable tolerability profiles.
Over 80 therapeutic peptides are in active clinical use. Three classification axes applied simultaneously make sense of them.
Function answers what a peptide does in the body. It is the most clinically useful axis because it maps directly to patient goals.
Route answers how the peptide enters the body. It determines bioavailability, dosing strategy, and cost.
Regulatory status answers whether and how you can legally access the peptide in the US. It determines your actual pathway to obtaining it.
A single peptide occupies all three axes at once. Body Protection Compound-157 (BPC-157), for example, is a healing peptide (function), primarily injectable (route), and compounded/research-grade (regulatory status). Understanding its position on each axis answers the three questions that actually matter: does it do what I need, can I tolerate how I take it, and can I get it legally?
Structural note: Within the 2–50 amino acid range, peptides further classify as oligopeptides (2–10 amino acids) or polypeptides (11–50 amino acids). Some have cyclic backbones — the chain loops back on itself, protecting against enzymatic breakdown. Cyclic structures are increasingly common in drug development for exactly this reason.
Learn more about how peptide structure affects stability and delivery options.
Classification by function: 7 therapeutic categories
Key takeaways
- Seven categories cover the full therapeutic range; several peptides appear in more than one due to overlapping mechanisms.
- GLP-1 agonists (semaglutide, tirzepatide) carry the strongest clinical evidence: Phase III trials showed approximately 15% (STEP 1) and up to 22.5% (SURMOUNT-1) mean body weight reduction respectively.
- FDA-approved compounds exist in four of the seven categories. The remaining three are accessed via compounding pharmacies under physician prescription.
- PeptideRx rates the evidence for GLP-1 agonists in weight management as Grade A. Compounded growth hormone secretagogues rate Grade B. Healing, anti-aging, and cognitive peptides currently rate Grade C.
Function is the starting point for every clinical decision. The seven categories below are not mutually exclusive — several peptides appear in more than one, reflecting genuinely broad mechanisms rather than classification ambiguity. Each peptide has a primary category that reflects its dominant mechanism and most common prescribed indication.
| Category | Primary mechanism | Key compounds | FDA-approved example | Evidence grade |
|---|---|---|---|---|
| Growth hormone | Stimulate pituitary GH release via GHRH-R or GHS-R1a | Sermorelin, CJC-1295, Ipamorelin, GHRP-2, GHRP-6 | Tesamorelin (Egrifta) | Grade B (compounded); Grade A (tesamorelin) |
| Weight loss | GLP-1R agonism → appetite suppression + insulin release | Semaglutide, Tirzepatide | Wegovy, Ozempic, Zepbound | Grade A |
| Healing & recovery | Angiogenesis, cell migration, collagen repair | BPC-157, TB-500, GHK-Cu | None (compounded) | Grade C |
| Anti-aging | Collagen synthesis, telomerase activation, skin signaling | GHK-Cu, Epitalon, Matrixyl | None (compounded/OTC) | Grade C |
| Cognitive | BDNF expression, anxiolytic signaling, neuroprotection | Semax, Selank | None (compounded) | Grade C |
| Immune & metabolic | Thymic immune modulation, mitochondrial activation | Thymosin Alpha-1, MOTS-c, KPV | None (compounded) | Grade B |
| Sexual health | MC4R agonism → central arousal signaling | PT-141 (Bremelanotide) | Vyleesi (FDA-approved) | Grade A |
Growth hormone
Growth hormone peptides form the largest clinical category. They split into two mechanistically distinct subclasses — GHRH analogs and GH secretagogues — covered in detail in the next section.
Weight loss
GLP-1 receptor agonists are the highest-evidence weight loss peptides available. Semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) both hold FDA approval for obesity and type 2 diabetes. Phase III trials showed approximately 15% mean body weight reduction for semaglutide over 68 weeks (STEP 1 trial, Wilding et al., N Engl J Med, 2021; PMID 33567185) and up to 22.5% for tirzepatide over 72 weeks (SURMOUNT-1, Jastreboff et al., N Engl J Med, 2022; PMID 35658024).
PeptideRx rates the evidence for GLP-1 agonists in weight management as Grade A — supported by multiple large Phase III randomized controlled trials with consistent results.
Healing and recovery
BPC-157 (15 amino acids) and TB-500 (thymosin beta-4) are the most studied compounds in this category. Both are frequently combined in the “Wolverine Stack” for their complementary mechanisms. Both are primarily studied in animal models; human randomized controlled trial data remains limited.
PeptideRx rates the evidence for BPC-157 and TB-500 in tissue healing as Grade C — based primarily on animal and in vitro data, with limited human clinical evidence.
Anti-aging
Anti-aging peptides overlap significantly with the healing category. GHK-Cu (glycine-histidine-lysine-copper complex) appears in both, given its roles in collagen signaling and wound repair. Epitalon (4 amino acids) has been studied for telomere-related mechanisms, but human data is limited.
PeptideRx rates the evidence across the anti-aging peptide category as Grade C.
Cognitive and neuroprotective
Semax and Selank were developed in Russia and have been used clinically there for decades. Both are delivered nasally, which enables central nervous system access via the olfactory pathway. Semax is a synthetic analog of ACTH(4-10); Selank is a tuftsin analog. Both are linked to brain-derived neurotrophic factor (BDNF) upregulation in animal models. US-based human trial data does not exist.
PeptideRx rates the evidence for Semax and Selank in cognitive function as Grade C — primarily animal model data, with no US-based human randomized controlled trials published.
Immune and metabolic
Thymosin Alpha-1 is used clinically in several countries for viral infections and immune dysregulation. MOTS-c is a mitochondria-derived peptide that activates AMP-activated protein kinase (AMPK) — a key metabolic regulator. MOTS-c is listed on the 2026 WADA Prohibited List under Section S4.4.1 (metabolic modulators).
PeptideRx rates the evidence for Thymosin Alpha-1 in immune support as Grade B — based on human clinical use outside the US with a plausible mechanism. MOTS-c rates Grade C.
Sexual health
PT-141 (bremelanotide) is a melanocortin-4 receptor (MC4R) agonist that activates central arousal pathways. It holds FDA approval as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few formerly compounded peptides to achieve full regulatory approval.
PeptideRx rates the evidence for PT-141 in sexual health as Grade A for its FDA-approved indication in premenopausal women with HSDD.
Learn more about how GLP-1 agonists compare for weight loss outcomes.
Growth hormone peptides: GHRH analogs vs. GH secretagogues
Key takeaways
- GHRH analogs bind the growth hormone-releasing hormone receptor (GHRH-R) on pituitary cells, producing GH pulses that preserve the body’s natural feedback loop.
- GH secretagogues activate the ghrelin receptor (GHS-R1a) through a different pathway — the two subclasses can be combined for additive GH output.
- The 2026 WADA Prohibited List (Section S2.2.4) explicitly bans all GHRH analogs and all GH secretagogues, including MK-677. Competitive athletes cannot use any compound in this category, regardless of prescription status.
Not all GH peptides work the same way — the receptor target is what separates them.
Both subclasses increase GH output from the pituitary, but they activate different receptors, produce different GH pulse profiles, and face different evidence tiers.
| Compound | AA count | Receptor target | Key distinction | Evidence tier |
|---|---|---|---|---|
| Sermorelin | 29 AA | GHRH-R | Oldest GHRH analog; historical FDA approval for pediatric GH deficiency | Clinical |
| CJC-1295 | 30 AA | GHRH-R | Long half-life (days) with DAC modification; widely used in compounding protocols | Compounded |
| Tesamorelin | 44 AA | GHRH-R | FDA-approved (Egrifta) for HIV-associated lipodystrophy; strongest RCT evidence in category | FDA-approved |
| Ipamorelin | 5 AA | GHS-R1a | GH secretagogue; selective, minimal cortisol/prolactin elevation | Compounded |
| GHRP-2 | 6 AA | GHS-R1a | Strong GH pulse; elevates cortisol and prolactin at higher doses | Compounded |
| GHRP-6 | 6 AA | GHS-R1a | Notable appetite-stimulating side effect via ghrelin receptor activation | Compounded |
| MK-677 (Ibutamoren) | Non-peptide | GHS-R1a | Oral ghrelin mimetic; acid-stable small molecule — not technically a peptide | Compounded |
GHRH analogs (sermorelin, CJC-1295, tesamorelin) bind the growth hormone-releasing hormone receptor on pituitary somatotroph cells, mimicking the natural GHRH signal. The resulting GH pulse respects the body’s feedback loop — elevated IGF-1 still suppresses further output, preventing runaway GH elevation.
GH secretagogues (ipamorelin, GHRP-2, GHRP-6, hexarelin) activate the ghrelin receptor (GHS-R1a) through a different receptor pathway. Combining a GHRH analog with a GH secretagogue produces additive GH output — the rationale behind the widely used CJC-1295/Ipamorelin protocol.
MK-677 is not technically a peptide. It is a non-peptide small molecule that mimics ghrelin and survives oral administration because of its acid-stable structure. It appears in GH secretagogue discussions because its mechanism and clinical effects mirror those of peptide-class GH secretagogues.
WADA status: The 2026 WADA Prohibited List (Section S2.2.4, in force January 1, 2026) explicitly prohibits all GHRH analogs and all GH secretagogues. This includes CJC-1295, sermorelin, tesamorelin, MK-677 (ibutamoren), ipamorelin, GHRP-2, GHRP-6, and hexarelin. Competitive athletes subject to WADA testing cannot use any compound in this category, regardless of prescription status or legitimate medical indication.
Learn more about how the CJC-1295/Ipamorelin protocol works and what the research shows.
Nutraceutical and food-derived peptides
Bioactive food peptides occupy a separate category from therapeutic peptides — same chemistry, different regulatory pathway.
Marine, dairy, and plant-derived peptides are released when food proteins are broken down during digestion or food processing. These short peptide fragments have measurable biological activity — antioxidant effects, blood pressure modulation, collagen synthesis signaling — but they are regulated as dietary supplements under DSHEA (the Dietary Supplement Health and Education Act), not as prescription drugs.
Three main sources:
- Marine-derived: Fish collagen hydrolysates (primarily type I collagen fragments) and fish peptides with antioxidant and anti-inflammatory properties.
- Dairy-derived: Casein phosphopeptides (CPPs) from milk, and whey-derived peptides with ACE-inhibitory and calcium-absorption properties.
- Plant-derived: Soy and wheat peptides with antioxidant and antihypertensive effects in animal and some human studies.
Hydrolyzed collagen supplements — the “collagen peptides” on supplement labels — contain peptide fragments of typically 2 to 10 amino acids produced by enzymatic breakdown of collagen protein. These are not intact collagen (which cannot be absorbed intact), but peptide fragments that reach systemic circulation.
The key regulatory distinction: nutraceutical peptides make functional claims under supplement law (“supports joint health”), not therapeutic claims under drug law (“treats osteoarthritis”). For anyone exploring therapeutic applications, nutraceutical peptides represent a separate evidence and access pathway from physician-prescribed compounding peptides.
Learn more about the difference between nutraceutical collagen peptides and injectable BPC-157.
Classification by administration route
Key takeaways
- SubQ injection delivers 90–100% bioavailability and is the standard for most therapeutic peptides.
- Oral semaglutide (Rybelsus) achieves only 0.4–1% bioavailability with SNAC absorption technology — the most bioavailability-optimized oral peptide formulation currently available (FDA prescribing information, 2024).
- MK-677 survives oral administration because it is an acid-stable non-peptide small molecule, not because of a specialized delivery technology.
- Nasal delivery (Semax, Selank) provides an estimated 10–25% bioavailability and offers a direct CNS access pathway via the olfactory route.
How a peptide enters the body determines how much of it actually reaches its target.
Most peptides are broken down by digestive enzymes and stomach acid when swallowed. Injection bypasses this problem entirely. Each route involves a tradeoff between bioavailability, convenience, and clinical utility.
| Route | Bioavailability | Examples | Reconstitution required? | Advantages | Limitations |
|---|---|---|---|---|---|
| SubQ injectable | 90–100% | Semaglutide (Ozempic), CJC-1295, Ipamorelin, BPC-157 | Yes (lyophilized powder + BAC water) | Highest bioavailability; most peptides available this way | Needles; reconstitution process; injection site rotation |
| Oral | 0.4–1% (semaglutide with SNAC) to ~15% (MK-677) | Oral semaglutide (Rybelsus), MK-677, BPC-157 oral | No | Needle-free; convenient | Severe degradation; strict dosing requirements; most peptides don’t survive digestion |
| Nasal | 10–25% (estimated) | Semax, Selank, PT-141 nasal (off-label) | No | Direct CNS access via olfactory pathway; needle-free | Lower and variable bioavailability; not suitable for most peptides |
| Topical | Variable; primarily localized | GHK-Cu serums, Matrixyl | No | No systemic exposure; targets skin directly | Minimal systemic effect; limited to dermal applications |
SubQ injectable is the gold standard for therapeutic peptides. Lyophilized powder (freeze-dried peptide) is reconstituted by adding bacteriostatic water (BAC water) to the vial, then drawing doses into insulin syringes for subcutaneous injection — typically into abdominal fat, thigh, or deltoid.
Oral delivery faces a steep bioavailability challenge. Oral semaglutide (Rybelsus) uses SNAC — an absorption enhancer that buffers stomach pH and temporarily opens the gastric epithelium — to achieve 0.4–1% bioavailability (FDA prescribing information, 2024; PMC10788673). MK-677 survives oral administration because it is a non-peptide small molecule with an acid-stable structure, not because of a delivery technology. BPC-157 shows adequate gastrointestinal tissue exposure when taken orally, which is why it is sometimes used for gut-targeted applications — though systemic bioavailability remains lower than injectable.
Nasal delivery is used primarily for brain-targeted peptides. The olfactory region provides a shorter pathway to the central nervous system than systemic circulation — the rationale for intranasal Semax and Selank. Bioavailability estimates of 10–25% reflect that nasal mucosa absorption is variable and formulation-dependent.
Note on nasal bioavailability estimates: The 10–25% range reflects current literature estimates. A PubMed-indexed pharmacokinetics study for Semax or Selank nasal bioavailability should be confirmed before citing this figure in clinical contexts.
Topical delivery is limited to dermal applications. GHK-Cu and Matrixyl (palmitoyl pentapeptide-4) penetrate the stratum corneum because their short chain length and molecular weight fall below the dermal penetration threshold, enabling them to reach fibroblasts and signal collagen production locally — without meaningful systemic absorption.
Learn more about how to reconstitute peptides for subcutaneous injection.
Legal status in the US (2026)
Key takeaways
- Five regulatory tiers determine legal access: FDA-approved, 503A compounded, 503B compounded, research-grade (unregulated), and WADA-prohibited.
- 503A and 503B compounded peptides both require a valid prescription from a licensed physician. No compounded peptide is legally available without one.
- Research-grade peptides sold online carry no FDA quality oversight. Independent purity testing has found active ingredient concentrations varying widely — some products below 50% of the labeled compound.
- Licensed compounding pharmacies operating under USP (United States Pharmacopeia) 797/795 standards provide HPLC (high-performance liquid chromatography)-verified purity typically at 98% or above.
Legal access to a peptide depends entirely on which regulatory tier it occupies.
| Tier | Examples | Access pathway | Quality assurance | WADA risk |
|---|---|---|---|---|
| FDA-approved | Semaglutide (Wegovy/Ozempic), Tirzepatide (Zepbound), Tesamorelin (Egrifta), PT-141 (Vyleesi) | Prescription from licensed physician; filled at standard pharmacy; insurance may apply | Full FDA manufacturing oversight; defined purity standards | Semaglutide/Tirzepatide: not listed. Tesamorelin: S2.2.4 prohibited |
| 503A compounded | Sermorelin, CJC-1295, Ipamorelin, BPC-157, Thymosin Alpha-1, Selank, Semax | Valid prescription from licensed prescriber; filled by licensed 503A compounding pharmacy | USP (United States Pharmacopeia) 797/795 sterility standards; HPLC-verified purity typically 98%+ | Check each compound individually |
| 503B compounded | Larger-batch versions of 503A compounds | Valid prescription; filled by registered 503B outsourcing facility | Higher oversight than 503A; batch testing required | Same as 503A compounds |
| Research-grade | Same compounds as above; sold “for research use only” | No prescription required; purchased online | No FDA oversight; purity varies from below 50% to 99%+ | Same compounds; contamination risk adds health risk on top of WADA risk |
| WADA-prohibited | CJC-1295, Sermorelin, Tesamorelin, Ipamorelin, GHRP-2, GHRP-6, MK-677, TB-500, MOTS-c, AOD-9604 | Any of the above | Any of the above | Prohibited for competitive athletes subject to WADA testing |
503A vs. 503B: Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies that prepare patient-specific medications under a valid physician prescription. Section 503B covers registered outsourcing facilities that produce larger batches without patient-specific prescriptions, subject to stricter oversight. Both require a prescription for the end patient to legally use the product.
2026 reclassification update: In February 2026, HHS Secretary Kennedy announced that approximately 14 of the 19 peptides previously placed on the FDA’s Category 2 “do not compound” list would be moved back to Category 1 status. As of this writing, the formal FDA regulatory documentation had not been published. Access should remain through licensed prescribers and accredited compounding pharmacies only. PeptideRx will update this section when formal FDA documentation is published.
Grey market quality risk: Research-grade peptides sold online without a prescription have no FDA quality oversight. Independent purity testing has found active ingredient concentrations varying widely — some products contain less than 50% of the labeled peptide. Licensed compounding pharmacies operating under USP 797/795 standards typically provide HPLC-verified purity at 98% or above.
WADA prohibited status (2026 list, in force January 1, 2026)
| WADA section | Banned compounds |
|---|---|
| S2.2.3 — GH fragments | AOD-9604, hGH 176-191 |
| S2.2.4 — GH releasing factors | CJC-1295, sermorelin, tesamorelin, ipamorelin, MK-677 (ibutamoren), GHRP-2, GHRP-6, hexarelin |
| S2.3 — Growth factors | TB-500 (thymosin beta-4) and its derivatives |
| S4.4.1 — Metabolic modulators | MOTS-c |
Semaglutide, tirzepatide, BPC-157, Thymosin Alpha-1, Selank, Semax, and PT-141 are not currently listed on the 2026 WADA Prohibited List. Athletes should verify each compound at wada-ama.org or via Global DRO before starting any protocol — the list updates annually.
Learn more about how to verify a compound’s WADA status before starting a protocol.
Peptides that span multiple categories
Some peptides appear in more than one functional category — and that reflects their mechanism, not imprecise classification.
BPC-157, GHK-Cu, and a handful of others genuinely affect more than one physiological system. For protocol design, this offers efficiency: one compound addressing multiple goals simultaneously. The tradeoff is that multi-mechanism compounds may have broader side effect considerations to discuss with your physician.
| Peptide | Primary category | Secondary category | Tertiary category | Mechanism link |
|---|---|---|---|---|
| BPC-157 | Healing & recovery | Immune/metabolic (gut) | Cognitive (neuroprotective) | Angiogenesis mechanism drives healing; gut affinity drives GI applications; brain-gut axis explains neuroprotection data |
| GHK-Cu | Anti-aging (skin) | Healing & recovery (wound) | Anti-aging (hair) | Copper delivery mechanism drives collagen synthesis across all three applications |
| Tesamorelin | Growth hormone | Weight loss (visceral fat) | — | GHRH mechanism stimulates GH, which reduces visceral fat — the basis for its FDA indication in HIV-associated lipodystrophy |
| MOTS-c | Immune & metabolic | Anti-aging (cellular) | — | AMPK activation improves metabolic function and has documented effects on cellular aging markers |
| Thymosin Alpha-1 | Immune & metabolic | Anti-aging (immune restoration) | — | Thymic peptide mechanism affects both acute immune response and long-term immune aging |
BPC-157 is the most cross-category peptide in common use. Its 15-amino-acid sequence (a fragment of gastric protein BPC) stimulates angiogenesis — new blood vessel formation — which explains its effects across tendons, muscle, gut lining, and neurological tissue. Oral dosing works for gut applications because the peptide reaches gastrointestinal tissue at adequate local concentration before systemic breakdown occurs.
GHK-Cu earns its dual anti-aging/healing classification from its copper-chelating mechanism. The peptide carries copper ions to target cells, where copper activates enzymes involved in collagen cross-linking and wound healing. This is why GHK-Cu appears in both wound-healing research and anti-aging skincare — using the same compound.
Learn more about multi-peptide stacking protocols and the evidence behind them.
How to choose the right peptide
Start with your goal. Then apply the practical filters that determine whether a protocol is realistic for you.
Step 1 — Match your goal to a functional category:
| Your primary goal | Primary category | Best-evidence compounds |
|---|---|---|
| Body composition / GH optimization | Growth hormone | Tesamorelin (FDA-approved), Sermorelin, CJC-1295 + Ipamorelin |
| Weight loss | Weight loss (GLP-1) | Semaglutide (FDA-approved), Tirzepatide (FDA-approved) |
| Injury recovery / tendon repair | Healing & recovery | BPC-157, TB-500 |
| Skin quality / collagen | Anti-aging | GHK-Cu (topical), Matrixyl (topical) |
| Cognitive function / stress response | Cognitive | Semax, Selank |
| Immune support / gut health | Immune & metabolic | Thymosin Alpha-1, BPC-157 (oral) |
| Sexual function | Sexual health | PT-141 (FDA-approved as Vyleesi) |
Step 2 — Apply the practical filters:
| Filter | What to ask | Implications |
|---|---|---|
| Needle tolerance | Do you prefer oral or nasal delivery? | Oral options: oral semaglutide (Rybelsus, requires strict empty-stomach dosing), MK-677. Nasal: Semax, Selank. Most other therapeutic peptides require injection. |
| Budget | What is your monthly out-of-pocket budget? | FDA-approved compounds with insurance coverage may carry lower out-of-pocket cost. Compounded peptides typically range $50–$400/month. Branded tesamorelin (Egrifta) without insurance can exceed $1,500/month. |
| Evidence threshold | How important is Phase III RCT data to you? | Only FDA-approved compounds have completed Phase III trials. Compounded peptides like sermorelin and BPC-157 have clinical track records but limited RCT data. |
| Regulatory access | Do you have a licensed physician who can prescribe? | All 503A and 503B compounded peptides require a valid prescription. Research-grade sources are not a legal alternative for human use — and quality risk is real. |
| Athlete status | Do you compete in a WADA-governed sport? | Most GH peptides are prohibited. MOTS-c and TB-500 are prohibited. BPC-157 and GLP-1 agonists are currently not listed. Verify at wada-ama.org before starting any protocol. |
Learn more about how to evaluate a compounding pharmacy’s quality standards before ordering.
The bottom line
Therapeutic peptides cover a wide range of goals — from GH optimization and weight loss to tissue healing and cognitive support. The right starting point is matching your goal to the functional category with the strongest evidence for that application. FDA-approved options (semaglutide, tirzepatide, tesamorelin, PT-141) carry Phase III data; compounded options like sermorelin and BPC-157 have clinical track records but more limited trial data. Most therapeutic peptides require injection and a physician prescription — research-grade sources bypass both the quality controls and the legal framework that make compounded peptides appropriate for human use. Your next step is a conversation with a licensed physician who can evaluate your labs and goals.
Frequently asked questions
What is the difference between a peptide and a protein?
Size — peptides contain 2 to 50 amino acids; proteins exceed 50 and fold into complex three-dimensional structures that enable them to function as enzymes, antibodies, and structural scaffolding. Both are broken down by digestive enzymes, which is why oral delivery is challenging for each. The smaller size of peptides makes engineering oral formulations slightly more tractable, but significant degradation still occurs in most cases.
Can peptides be taken orally, or do they all require injection?
No, not all — but most do. Stomach acid and digestive enzymes break the peptide bond before systemic absorption occurs in the majority of cases. Oral exceptions work through structural workarounds: MK-677 is a non-peptide small molecule with an acid-stable structure; oral semaglutide uses SNAC absorption technology to achieve 0.4–1% bioavailability (FDA, 2024); and BPC-157 has documented gastrointestinal tissue activity via oral dosing. Nasal delivery (Semax, Selank) bypasses digestion and targets the CNS via the olfactory pathway.
Are peptides legal to obtain in the US without a prescription?
No — for therapeutic peptides. FDA-approved peptides require a prescription. Compounded peptides (503A/503B) also require a valid prescription from a licensed prescriber. Nutraceutical peptides (hydrolyzed collagen, food-derived bioactive peptides) are available over-the-counter as dietary supplements, but these are not the same as therapeutic peptides. Research-grade peptides are sold legally online “for research use only,” but they are not approved for human administration under FDA rules, and their purity is unregulated.
Are peptides banned in sports?
Many are. The 2026 WADA Prohibited List (in force January 1, 2026) bans all GH-releasing hormones and their analogs under S2.2.4, all GH secretagogues (including ipamorelin and MK-677), TB-500 under S2.3, AOD-9604 under S2.2.3, and MOTS-c under S4.4.1. Semaglutide and BPC-157 are not currently listed. Verify current status at wada-ama.org before starting any protocol — the list updates annually.
What is the lowest-risk peptide category for someone starting out?
FDA-approved peptides carry the lowest risk profile. Semaglutide (Ozempic/Wegovy), tirzepatide (Zepbound/Mounjaro), tesamorelin (Egrifta), and PT-141 (Vyleesi) have all completed Phase III clinical trials with defined safety and efficacy data. Compounded peptides like sermorelin and ipamorelin have favorable clinical records but less trial data than their FDA-approved counterparts. Regardless of compound, avoid research-grade or grey market sources — quality control deficiencies add health risk on top of regulatory risk.
How do peptides differ from anabolic steroids and SARMs?
Peptides signal within existing physiological feedback systems. GH peptides stimulate the pituitary to produce more GH — but elevated IGF-1 still suppresses further output, preserving the regulatory loop. Anabolic steroids, by contrast, directly replace or amplify testosterone and suppress the HPG axis (hypothalamic-pituitary-gonadal axis), causing endogenous testosterone production to fall. SARMs (selective androgen receptor modulators) activate androgen receptors with tissue specificity but similarly bypass normal feedback regulation — giving peptides a generally milder hormonal footprint than either alternative.
What do structural terms like “oligopeptide” and “cyclic peptide” mean in practice?
Oligopeptide means a chain of 2–10 amino acids; polypeptide means 11–50. Ipamorelin (5 amino acids) is an oligopeptide; tesamorelin (44 amino acids) is a polypeptide — and that size difference directly affects how they can be delivered and how long they last in circulation. Cyclic peptides have a backbone that loops back on itself, which protects the compound from enzymatic breakdown. That structural stability is a key reason cyclic designs are increasingly common in drug development.
Considering peptide therapy? Speak with a licensed physician who can review your labs and discuss whether any peptide protocol is appropriate for your specific situation.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (STEP 1 trial — ~15% body weight reduction with semaglutide 2.4 mg)
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (SURMOUNT-1 — up to 22.5% body weight reduction)
- Rybelsus (semaglutide) prescribing information. FDA label, 2024. Absolute bioavailability 0.4–1%.
- Brayden DJ, et al. Current understanding of SNAC as an absorption enhancer: the oral semaglutide experience. Diabetes Ther. 2024;15:193–228. PMC10788673.
- Sánchez Lorente J, et al. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025;24(6):458-479.
- WADA 2026 Prohibited List (in force January 1, 2026). Sections S2.2.3, S2.2.4, S2.3, S4.4.1. wada-ama.org.
- Al Musaimi O, et al. 2025 FDA TIDES harvest. Pharmaceuticals. 2026;19(2):244. PMC12898419. (~130 FDA-approved peptides as of 2025.)
- Nasal peptide bioavailability (10–25% range): cited in brief without primary source. PubMed-indexed study required for Semax/Selank nasal BA before publication.
- BPC-157 oral GI activity: mechanism claim requires PubMed PMID. Animal model data should be distinguished from human clinical data.
- Grey market purity range (below 50% vs 98%+): cited in brief. An independent testing source or published analysis is needed to support this comparison before publication.
- MOTS-c WADA S4.4.1 status: confirmed via WADA 2026 Prohibited List (S4.4.1 reads “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)”). Citation: wada-ama.org.
Disclaimer: The information on this page is for educational purposes only. We do not provide medical advice, diagnoses, or treatment recommendations. All therapeutic peptides discussed require physician prescription for legal human use. Regulatory status reflects available information as of March 2026 and is subject to change. The February 2026 HHS reclassification announcement has not yet been formalized in FDA regulatory documentation — legal compounding eligibility has not officially changed as of this writing. Verify current WADA status for any compound via wada-ama.org before use in competition. PeptideRx directs all readers toward licensed telehealth providers and licensed compounding pharmacies operating under 503A/503B of the Federal Food, Drug, and Cosmetic Act.